EFPIA - NEWSLETTER

Trouble reading this email? View it in your browser


		EFPIA Newsletter 19 May 2022

International Clinical Trials Day

Enhancing public health through responsible Clinical Trials Data Sharing
19 May 2022

International Clinical Trials Day: EFPIA’s commitment to advancing data transparency in a changing world Read more

Digital Health Technologies in Drug Development
19 May 2022

Accelerating the momentum in Europe Read more

Complex Clinical Trials – A decade of innovation in clinical research
19 May 2022

From a Drug centric to a Patient centric approach Read more

#WeWontRest until we beat cancer

Bladder Cancer Awareness Month: an opportunity for collaborative action to address pressing...
17 May 2022

As our understanding of predictive biomarkers grows, we have the potential to change what a cancer diagnosis means for... Read more

Bladder cancer: the Cinderella of cancers
18 May 2022 - Alan McDougall

Prioritising bladder cancer in EU health policy and research frameworks can help reduce disease burden and support progress... Read more

Revising the EU Council Recommendation on cancer screening: an opportunity to step up the fight...
16 May 2022 - Catherine Owen

We are committed to working with all stakeholders to achieve tangible progress for patients with cancer, keeping the... Read more

Events

mportance of Diversity & Equal Opportunities in a Healthy R&D Environment - Workforce and Organizational...
02 June 2022 (June 2, 14:00-15:30 CET)

Workforce and Organizational Culture Read more

Future Clinical Trials conference – from tomorrow to 2030 – Why choose the Nordics?
07 June 2022 (in Helsinki or virtually)

The event will take place in Team Finland House (Porkkalankatu 1, Helsinki). It is also possible to follow the event... Read more

We published

Cardiovascular disease (CVD) is Europe’s number one killer, taking the lives of 5,000 Europeans every day. A new report by PwC, commissioned by the EFPIA CVD Network, set out to understand the impact of the pandemic on the 60 million CVD patients living in Europe. More than that, the report – Boosting cardiovascular health in Europe: towards more resilient and equitable healthcare – offers a series of concrete recommendations designed to better position European health systems to cope with future crises.

What we are reading

France is making innovative drugs more accessible, but it can still do better
On 16 May 2022 (Le Monde)

It takes an average of 497 days in France for a new treatment approved by the European Medicines Agency to actually... Read more

Finance, culture, talent: why Europe struggles to commercialise its biotech expertise
On 21 March 2022 (Financial Times)

The continent is eager to capitalise on BioNTech’s Covid-19 success — but matching the scale of US hubs will be hard... Read more

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
E-mail:Communications@efpia.eu